Device Oncology

Oncomate Msi Dx Analysis System

Payments companies reported to CMS as associated with Oncomate Msi Dx Analysis System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$387associated payments (2023-2025)
11clinicians with associated payments
1company reporting

By year

2023 $185
2024 $202

Payments reported as associated with Oncomate Msi Dx Analysis System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Anatomic Pathology & Clinical Pathology $252
Psychiatry $98.05
Anatomic Pathology $14.63

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Oncomate Msi Dx Analysis System

These are the largest totals companies reported as associated with Oncomate Msi Dx Analysis System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Jessica Jeffrey Los Angeles, CA Psychiatry $98.05
Devon Chabot-Richards Albuquerque, NM Anatomic Pathology & Clinical Pathology $53.12
Maria Del Carmen Frias Kletecka Los Angeles, CA Anatomic Pathology & Clinical Pathology $43.50
Artur Rangel Filho Hollywood, FL Anatomic Pathology & Clinical Pathology $35.84
Antonios Papanicolau-Sengos Hollywood, FL Anatomic Pathology & Clinical Pathology $35.84
Robert Veve Murrieta, CA Anatomic Pathology & Clinical Pathology $28.50
Ryan Rebbe Los Angeles, CA $22.62
Jordan Redemann Albuquerque, NM Anatomic Pathology & Clinical Pathology $22.62
Sumra Rathore Jacksonville, FL Anatomic Pathology & Clinical Pathology $16.15
Cindy Davis Jacksonville, FL Anatomic Pathology & Clinical Pathology $16.15

Prescribed Oncomate Msi Dx Analysis System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.